Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Sophie Betteridge"'
Publikováno v:
Trials, Vol 21, Iss 1, Pp 1-8 (2020)
Abstract Background Nocebo effects (‘negative placebo’ effects) experienced by clinical trial participants can arise from an underlying condition or through communication about side effects in the participant information leaflets (or elsewhere).
Externí odkaz:
https://doaj.org/article/5dcf07e32fcb43a8932b04d2fade9f9d
Autor:
Paul Ferguson, Robert K. Hills, Angela Grech, Sophie Betteridge, Lars Kjeldsen, Michael Dennis, Paresh Vyas, Anthony H. Goldstone, Donald Milligan, Richard E. Clark, Nigel H. Russell, Charles Craddock
Publikováno v:
Haematologica, Vol 101, Iss 11 (2016)
Up to 30% of adults with acute myeloid leukemia fail to achieve a complete remission after induction chemotherapy - termed primary refractory acute myeloid leukemia. There is no universally agreed definition of primary refractory disease, nor have th
Externí odkaz:
https://doaj.org/article/f772d011430040108f48560b445e89d7
Autor:
Jad Othman, Charlotte S Wilhelm-Benartzi, Richard Dillon, Steven Knapper, Sylvie D Freeman, Leona M Batten, Joanna Canham, Emily L Hinson, Julie Wych, Sophie Betteridge, William Villiers, Michelle Kleeman, Amanda Frances Gilkes, Nicola Potter, Ulrik Overgaard, Priyanka Mehta, PANAGIOTIS KOTTARIDIS, Jamie Cavenagh, Claire Jane Hemmaway, Claire Arnold, Mike Dennis, Nigel H. Russell
Publikováno v:
Blood Advances.
Liposomal daunorubicin and cytarabine (CPX-351) improves overall survival (OS) compared to 7+3 chemotherapy in older patients with secondary acute myeloid leukaemia (AML); to date there have been no randomized studies in younger patients. The high-ri
Publikováno v:
Trials, Vol 21, Iss 1, Pp 1-8 (2020)
Trials
Trials
Background Nocebo effects (‘negative placebo’ effects) experienced by clinical trial participants can arise from an underlying condition or through communication about side effects in the participant information leaflets (or elsewhere). Misattrib
Autor:
Robert Kerrin Hills, Sophie Betteridge, Michael Dennis, Nigel H. Russell, Jelena V. Jovanovic, David Grimwade, Richard Dillon, Alan Kenneth Burnett
Publikováno v:
Russell, N, Burnett, A, Hills, R, Betteridge, S, Dennis, M, Jovanovic, J, Dillon, R & Grimwade, D 2018, ' Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL : long-term follow-up of the AML17 trial ', Blood, vol. 132, no. 13, pp. 1452-1454 . https://doi.org/10.1182/blood-2018-05-851824
We have previously reported on the results of the United Kingdom National Cancer Research Institute (NCRI) AML17 trial, which, for acute promyelocytic leukemia (APL) of all risk groups, compared anthracycline + all-trans retinoic acid (ATRA) (AIDA) v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc11a6974164a42acbe0ff41c4475eb6
https://doi.org/10.1182/blood-2018-05-851824
https://doi.org/10.1182/blood-2018-05-851824
Autor:
Sophie Betteridge, R Hills, Nigel H. Russell, Lars Kjeldsen, Tim E. Hawkins, Alan Kenneth Burnett, Richard E. Clark, P Cahalin, Steve Knapper, Marion Sweeney, Emma Das gupta, Asim Khwaja
Publikováno v:
Burnett, A K, Das Gupta, E, Knapper, S, Khwaja, A, Sweeney, M, Kjeldsen, L, Hawkins, T, Betteridge, S E, Cahalin, P, Clark, R E, Hills, R K, Russell, N H & UK NCRI AML Study Group 2018, ' Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia : experience from the UK NCRI AML17 trial ', Haematologica, vol. 103, no. 10, pp. 1654-1661 . https://doi.org/10.3324/haematol.2018.189514
As part of the UK NCRI AML17 trial, adult patients with acute myeloid leukemia in remission could be randomized to receive the mammalian target of rapamycin inhibitor everolimus, sequentially with post-induction chemotherapy. Three hundred and thirty
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c84be18d0b504ce7d586cd02b943a43
https://orca.cardiff.ac.uk/id/eprint/113163/1/haematol.2018.189514.full.pdf
https://orca.cardiff.ac.uk/id/eprint/113163/1/haematol.2018.189514.full.pdf
Autor:
Sophie Betteridge, Richard E. Clark, Donald Milligan, Michael Dennis, Charles Craddock, Angela Grech, Nigel H. Russell, Robert Kerrin Hills, Paresh Vyas, Lars Kjeldsen, Anthony H. Goldstone, Paul Ferguson
Up to 30% of adults with acute myeloid leukemia fail to achieve a complete remission after induction chemotherapy - termed primary refractory acute myeloid leukemia. There is no universally agreed definition of primary refractory disease, nor have th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bb4d67ae3050ddc4c2ea6ace6439bfa
https://ora.ox.ac.uk/objects/uuid:46c7e173-cb3b-48ad-896b-d4300b56508e
https://ora.ox.ac.uk/objects/uuid:46c7e173-cb3b-48ad-896b-d4300b56508e
Autor:
Sophie Betteridge, Michael Dennis, David Grimwade, Richard Dillon, Alan Kenneth Burnett, Robert Kerrin Hills, Nigel H. Russell
Publikováno v:
Blood. 128:897-897
Background: Two randomized studies have reported comparison of the "chemo-free" combination of ATO+ATRA with Anthracycline/ ATRA (AIDA) in APL. The GIMEMA-AMLSG-SAL trial, using a daily schedule improved both survival and relapse risk in patients wit
Autor:
Paul Ferguson, Anthony H. Goldstone, Paresh Vyas, Richard E. Clark, Charles Craddock, Donald Milligan, Michael Dennis, Sophie Betteridge, Alan Kenneth Burnett, Lars Kjeldsen, Nigel H. Russell, Angela Grech, Robert Kerrin Hills
Publikováno v:
Blood. 126:559-559
Purpose Resistance to induction chemotherapy (IC) is an important adverse prognostic factor in adults with newly diagnosed acute myeloid leukaemia (AML), particularly older patients. Despite its therapeutic relevance there is however no universally a